Australia markets closed

Cipla Limited (CIPLA.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
978.40+40.40 (+4.31%)
At close: 03:29PM IST

Cipla Limited

Cipla House
Peninsula Business Park Ganpatrao Kadam Marg Lower Parel
Mumbai 400013
India
91 22 2482 6000
https://www.cipla.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Umang VohraMD, Global CEO & Exec. Director181.3MN/A1971
Ms. Samina HamiedExec. Vice-Chairperson81.5MN/A1976
Dr. Raju Sunil Mistry M.A., Ph.D.Pres & Global Chief People OfficerN/AN/A1965
Mr. Pradeep BhadauriaPres & Chief Scientific OfficerN/AN/AN/A
Mr. Dinesh Ramniranjan JainSr. VP, Interim CFO & Head of Corp. Fin.N/AN/AN/A
Ms. Geena V. MalhotraGlobal Chief Technology OfficerN/AN/AN/A
Mr. Naveen BansalHead of Investor RelationsN/AN/AN/A
Mr. Gautam RohidekarChief Legal OfficerN/AN/AN/A
Mr. Rajendra Kumar ChopraCompliance Officer & Company Sec.N/AN/AN/A
Ms. Heena KanalVP of Corp. CommunicationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.

Description

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19; partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19; licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.

Corporate governance

Cipla Limited’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 3; Board: 1; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.